SITC 2021 – Immatics’ T-cell receptor success was no fluke

After a long gestation T-cell receptor-based cell therapies were shown, courtesy of Adaptimmune and Immatics, to have a future after all. Today the latter company followed up an arguable early success with the project IMA203 by revealing improved signs of efficacy in more patients. A just unveiled late-breaker at the SITC conference includes 16 evaluable subjects with highly refractory solid tumours, eight of whom went into remission on treatment with IMA203, though four quickly relapsed. The data concerned the first three doses, the first of which elicited no responses; even so, a resulting 50% ORR for a TCR project in solid tumours looks impressive. In March a partial remission among the first four subjects given IMA203, an engineered TCR targeting the PRAME antigen, helped send Immatics up 30%. On an investor call Immatics said it would expand cohorts in five undisclosed cancers, and while initial efficacy was promising the next update, at dose level 4 and with six-month follow-up, would focus on durability. While initially Immatics stock shot up 25% it was off 9% in early trade. Developers of other PRAME-directed projects will be taking note.

Selected engineered projects targeting PRAME
Company Project Modality Clinical trial Note
Immatics IMA203 eTCR (HLA-A*02-specific) NCT03686124 50% ORR (62% at highest doses); also has IMA203CD8
Medigene MDG1011 eTCR (HLA-A*02:01-specific) NCT03503968 Topline data by end 2021; also has MDG1014
Immunocore IMC-F106C Immtac (HLA-A*02:01-specific) NCT04262466 Initial data mid-2022
Bellicum BPX-701 eTCR (HLA-A*02:01-specific; rimiducid-activated suicide switch) NCT02743611 Deprioritised
Glaxosmithkline/ Adaptimmune PRAME TCR eTCR NA No clinical trial; status unclear
Source: company filings &
Source: Immatics.

Share This Article